CARDIOPROTECTIVE MECHANISMS OF EMPAGLIFLOZIN IN PATIENTS WITH TYPE 2 DIABETES MELLITUS AND ISCHEMIC HEART DISEASE

Authors

  • Mekhribon Khayrilloeva Author
  • Nematulla Bobokambarov Author
  • Buron Lapasov Author

Keywords:

To analyze the pharmacological mechanisms of cardioprotective action of empagliflozin in patients with T2DM and IHD

Abstract

Type 2 diabetes mellitus (T2DM) significantly increases the risk of ischemic heart disease (IHD). Traditional hypoglycemic therapy often fails to reduce cardiovascular risk, which necessitates the use of drugs with proven cardioprotective effects

Downloads

Published

2026-06-04

Issue

2026: INDICATORS OF LATENT COURSE OF HIV INFECTION AMONG YOUTH AND EPIDEMIOLOGICAL FACTORS AFFECTING EARLY DETECTION

Section

Articles